Think Bioscience, a Boulder, Colorado-based biotechnology company developing small-molecule drugs against historically difficult targets, has raised $55 million in an oversubscribed Series A financing to advance its internal pipeline of first-in-class programs.
The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors included AV8 Ventures, CU Innovations, and Buff Gold Ventures.
Think Bioscience said it is applying a synthetic biology-driven approach to drug discovery designed to identify previously unseen “footholds” on proteins—such as novel binding pockets—that can enable medicinal chemistry programs where conventional approaches have struggled. The company positions the platform as a way to expand the addressable landscape beyond proteins commonly viewed as “undruggable,” even amid recent advances in computational chemistry and drug design.
The company’s lead program targets mutants associated with Noonan syndrome, a genetic condition that affects roughly 1 in 2,500 births and can involve serious cardiac and lymphatic complications, short stature, cognitive impairment, and chronic pain. Think Bioscience said there are currently no approved therapies that address the underlying biology of the disease.
Beyond its lead effort, Think Bioscience said it has extended its platform across a range of target classes, including transcription factors, protein phosphatases, kinases, proteases, and GTPases, as it builds out a broader internal pipeline.
KEY QUOTES:
“Our lead program has the potential to give a broad set of Noonan patients a better life. We are grateful to our investors for supporting our vision to develop life-changing therapies.”
Dr. Jerome Fox, Co-Founder and CEO, Think Bioscience
“This team is succeeding where others have failed. The lead program is the best example, but just one of many that the company is prosecuting. We are enthusiastic to double down.”
Nick Olsen, Partner, Innovation Endeavors
